Tenaya Therapeutics (TNYA) Cash & Equivalents (2020 - 2026)

Tenaya Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $80.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 50.45% year-over-year to $80.9 million; the TTM figure through Mar 2026 stood at $80.9 million (up 50.45% YoY), while the FY2025 annual figure was $100.5 million, up 2225.86% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $80.9 million, down from $100.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $100.5 million in Q4 2025, with the low at $4.3 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $58.1 million (2024), against an average of $56.2 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents sank 90.54% in 2024, then soared 2225.86% in 2025.
• Tenaya Therapeutics' Cash & Equivalents stood at $95.3 million in 2022, then slumped by 52.05% to $45.7 million in 2023, then tumbled by 90.54% to $4.3 million in 2024, then jumped by 2225.86% to $100.5 million in 2025, then dropped by 19.54% to $80.9 million in 2026.
• Business Quant data shows TNYA's Cash & Equivalents at $80.9 million in Q1 2026, $100.5 million in Q4 2025, and $56.3 million in Q3 2025.